Vyome Holdings, Inc. (NASDAQ: HIND) announced that China's National Intellectual Property Administration has granted the company a patent covering formulation and therapeutic use claims for its besifloxacin topical gel program for inflammatory acne.

The patent, numbered ZL 2021 1 0758695.X, includes claims directed to the treatment of inflammatory acne, inflammation associated with acne, and acne involving antibiotic-resistant Propionibacterium acnes.

According to the company's press release, China's prescription acne market is estimated at approximately $600 million annually by 2035, based on third-party data.

Venkat Nelabhotla, Vyome's chief executive officer, said the patent "further enhances our strategic optionality in the immuno-inflammation space without changing our operating priorities or requiring any significant incremental investment."

The Cambridge, Mass.-based company stated that its flagship program remains VT-1953, a therapy for malignant fungating wounds, which it described as the primary focus for capital and clinical development. The company indicated the new patent is intended to support potential partnering, licensing, and regional commercialization through what it described as "predominantly non-dilutive pathways."

Dr. Shiladitya Sengupta, Vyome co-founder and associate professor of medicine at Harvard Medical School, said the patent "substantially strengthens our existing patent estate by adding meaningful formulation and therapeutic use protection around our proprietary besifloxacin topical platform."